Oraya Therapeutics INTREPID Study Demonstrates Two-Year Safety and Effectiveness of Non-Invasive Therapy for Wet AMD
9/25/2013 9:42:50 AM
NEWARK, Calif.--(BUSINESS WIRE)--Oraya® Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD). These results provide continued evidence of a favorable safety profile and the therapy’s ability to reduce the frequency of anti-vascular endothelial growth factor (VEGF) injections in the eye. The broadly inclusive cohort of non-naïve wet AMD patients continued to receive the benefit of a 25 percent mean reduction in anti-VEGF injections over two years. Patients identified in the first year as ideal response candidates maintained an impressive 45 percent mean reduction in anti-VEGF injections through the two-year visit, with superior vision to the non-treated group. In addition, the overall safety profile was positive, with only one percent of treated patients showing evidence of micro-vascular abnormalities due to radiation that could affect vision outcomes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by